BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
Sorriso is a biopharmaceutical company advancing a pipeline of disease-modifying antibodies for the treatment of immune-mediated diseases, including Crohn’s disease and ulcerative colitis. The company's platform generates potent antibodies that can be delivered orally and are designed to maintain activity throughout the human intestine.
© 2025 Pappas Capital, LLC. ALL RIGHTS RESERVED.